Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis
Osteoporosis International · 2024
DOI: 10.1007/s00198-024-07161-x ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Osteoporosis International, 2024. Verfasst von Jean-Yves Reginster und 17 weiteren Autor:innen. Beteiligte Einrichtung: College of Sciences, King Saud University, Riyadh, Kingdom of Saudi Arabia. Hauptthemen laut MEDLINE: Denosumab, Biosimilar Pharmaceuticals, Osteoporosis, Postmenopausal, Bone Density Conservation Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Celltrion, Cedars-Sinai Medical Center.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Sciences, King Saud University, Riyadh, Kingdom of Saudi Arabia.
- Krakowskie Centrum Medyczne, Kraków, Poland.
- Department of Rheumatology, Medical University of Łódź, Łódź, Poland.
- Department of Perinatology and Gynaecology, Poznań University of Medical Sciences, Poznań, Poland.
- Centrum Medyczne Pratia Poznań, Poznań, Poland.
- Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine.
Förderung
- Celltrion
- Cedars-Sinai Medical Center
Zitieren
APA
Reginster, J. Y., Czerwinski, E., Wilk, K., Borowy, P., Strzelecka, A., Budlewski, T., Janowska-Maus, M., Szymanowski, K., Kwiatek, J., Postol, S., Põder, A., Supronik, J., Kim, S., Suh, J., Han, N., Kim, N., Bae, S., & Silverman, S. L. (2024). Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis. Osteoporosis International. https://doi.org/10.1007/s00198-024-07161-x
Vancouver
Reginster JY, Czerwinski E, Wilk K, Borowy P, Strzelecka A, Budlewski T, et al. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis. Osteoporosis International. 2024. doi:10.1007/s00198-024-07161-x
BibTeX
@article{Reginster2024,
author = {Reginster, Jean-Yves and Czerwinski, Edward and Wilk, Krzysztof and Borowy, Przemysław and Strzelecka, Anna and Budlewski, Tomasz and Janowska-Maus, Monika and Szymanowski, Krzysztof and Kwiatek, Joanna and Postol, Svitlana and Põder, Airi and Supronik, Jerzy and Kim, SungHyun and Suh, JeeHye and Han, NooRi and Kim, NaHyun and Bae, SeoHee and Silverman, Stuart L},
title = {Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis},
journal = {Osteoporosis International},
year = {2024},
doi = {10.1007/s00198-024-07161-x}
}
EUVIMED